Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →BPC-157 (Body Protection Compound-157, also called pentadecapeptide BPC 157) is an investigational peptide that is not FDA-approved, so there is no officially established human dose.[1] In published research and peptide-clinic reports, subcutaneous amounts of roughly 200–500 mcg, once or twice daily, are commonly described for educational reference, often in cycles of 4–8 weeks.[3] Oral forms are discussed but are less studied in humans. Almost all efficacy evidence comes from animal models, and long-term human safety is unknown.[3][4] Any decision about whether BPC-157 is appropriate, and at what amount, must be made by a licensed clinician based on your individual situation.
What is BPC-157 and why does dosing vary?
BPC-157 is a synthetic peptide of 15 amino acids (a "pentadecapeptide") derived from a protein sequence identified in human gastric juice.[3] It belongs to the broader category of longevity and tissue-repair peptides studied alongside compounds like TB-500 and GHK-Cu. In animal models it has been investigated as a candidate for tendon, ligament, muscle, and gastrointestinal tissue repair — it is not approved to treat any of these conditions.[3][4] No large, well-controlled human clinical trials have been completed, so no human dose has been validated, and reported animal benefits do not automatically translate to humans. Reported tolerability in animals also does not rule out unknown long-term risks in people, and side effects described later in this article apply regardless of the goal.
Amounts described in practice come from three sources: animal-study conversions, peptide-clinic protocols, and self-reported user data — none of which substitute for regulatory approval or individualized clinical evaluation. Approaches vary because the goal, route (injection vs oral), body weight, product purity, and individual medical history all differ. See our overview of longevity peptides for broader context on how this category is studied.
Is there an FDA-approved dose for BPC-157?
No. BPC-157 has not been approved by the U.S. Food and Drug Administration for any medical use.[1] In 2023, the FDA reviewed BPC-157 as part of its bulk substances list for compounding and placed it in Category 2, meaning the agency identified significant safety concerns that may make it ineligible for routine compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.[2] On April 15–16, 2026, the FDA announced a reclassification review of several peptides on the 503A bulk substances list, and the Pharmacy Compounding Advisory Committee (PCAC) is currently scheduled to discuss BPC-157's inclusion on the 503A Bulks List on July 23–24, 2026.[7] This is a forward-looking regulatory process — not an approval — and the outcome is not guaranteed. Our explainer on the FDA bulk substances list covers what Category 1 and Category 2 mean for patients.
What dosage ranges are described in research and compounding practice?
The ranges below summarize what is described in peptide research literature and clinic reports.[3] They are presented for educational context only — they are not endorsements, not recommendations, and not a substitute for clinician guidance. There are no controlled human trials confirming any of these amounts are safe or effective. Side effects (including injection-site reactions, nausea, headaches, and dizziness) and unknown long-term risks apply across all routes, and contraindications listed later in this article apply regardless of route.[3]
| Route | Range described in literature | Frequency described | Notes |
|---|---|---|---|
| Subcutaneous injection | 200–500 mcg per administration | 1–2x daily | Most commonly described route in peptide literature; typically uses an insulin syringe. Human RCTs lacking.[3] |
| Oral capsule | 250–500 mcg per administration | 1–2x daily | Less supporting evidence; human bioavailability not well established.[3] |
| Intramuscular injection | 200–500 mcg per administration | 1x daily | Described in some protocols; no clear human evidence of superiority and added injury risk. |
| Localized (near area of concern) | 200–300 mcg per administration | 1x daily | Described in some clinic protocols; human data very limited and injection technique carries risk. |
Subcutaneous injection ranges
Subcutaneous (under-the-skin) injection is the most frequently described route in the peptide literature. Reported single amounts cluster around 200–500 mcg.[3] Injections are typically described as being given into abdominal fat using a small U-100 insulin syringe. The most commonly reported side effect is injection-site irritation; nausea, headaches, and dizziness have also been described, and long-term effects in humans are unknown.[3] Reported animal benefits do not establish human efficacy, and human RCTs are lacking.
Oral capsule ranges
Oral BPC-157 capsules are sometimes prepared in 250 mcg and 500 mcg strengths. Some animal data suggest BPC-157 may remain relatively stable in stomach acid, but human bioavailability has not been well established.[3] Oral use has been investigated for gut-related research questions because the peptide may act locally on intestinal tissue. Gastrointestinal upset and headaches have been reported, and human efficacy is not established.[3]
Intramuscular and localized injection
Some protocols describe intramuscular or near-site injections. There is no strong human evidence that local injection is more effective than subcutaneous administration, and improper technique near a joint or tendon carries injury and infection risk. This is one reason a licensed clinician — not a generic chart — should guide route selection.
Is BPC-157 dosing adjusted by body weight?
Some clinicians scale BPC-157 by body weight; others use fixed amounts. Animal studies often use much higher per-kilogram amounts than what is described in humans, and animal doses do not translate directly to people.[3] Because human pharmacokinetic data is limited, any weight-based approach is approximate, the same unknown long-term risks apply at any weight, and side-effect risk is not eliminated by scaling. Your prescribing clinician will determine whether any approach is appropriate based on your individual situation.
How often is BPC-157 described as being taken?
Once vs twice daily
Both once-daily and twice-daily schedules are described in the literature.[3] There is no head-to-head human trial confirming one schedule is superior, and side-effect risk is not lower simply because an amount is split. Frequency, like the amount itself, should be set by a licensed clinician — not chosen from an online template.
Typical cycle length
Cycles of 4–8 weeks on, then 2–4 weeks off are the most commonly described pattern in peptide literature.[3] Cycling is precautionary — limiting any unknown long-term exposure — not based on confirmed receptor downregulation. Longer use has not been studied for safety in humans, and any cycle length should be determined by a clinician familiar with your medical history.
How is injectable BPC-157 reconstituted and measured?
Injectable BPC-157 is typically dispensed as a freeze-dried (lyophilized) powder in a sealed vial. It is reconstituted with bacteriostatic water — sterile water containing 0.9% benzyl alcohol — before use.[6] The amount of water added determines the concentration, which determines how many units on an insulin syringe correspond to each microgram.
Because small errors compound, reconstitution and dose measurement should be taught directly by the prescribing clinician or the dispensing pharmacy, who can match instructions to your specific vial strength. Generic charts found online may not match the product you receive, and this article intentionally does not provide reconstitution math. See our patient guide to bacteriostatic water and reconstitution for general background.
What are the side effects and risks at higher amounts?
Because BPC-157 has not undergone large human trials, its side-effect profile in people is poorly defined. Reported user- and clinic-level effects include injection-site irritation, mild nausea, headaches, dizziness, and changes in appetite or energy.[3] More frequent injection-site reactions and gastrointestinal upset have been described at higher amounts. None of these are well quantified in controlled human studies, and the absence of reported events is not the same as proven safety.[3]
Important unknowns include possible effects on blood vessel growth (angiogenesis), interaction with growth-related signaling pathways, and any long-term cancer risk. None of these have been confirmed or ruled out in humans.[5] This uncertainty is one reason the FDA flagged the peptide in its 2023 review.[2] Off-label and investigational use carries unknown long-term safety risks, and any reported benefit must be weighed against these unknowns.
Who should not use BPC-157?
- People who are pregnant, trying to become pregnant, or breastfeeding — safety has not been studied.
- Anyone with an active cancer diagnosis or recent cancer history, given theoretical concerns about tissue-growth and angiogenic signaling.[5]
- Children and adolescents — no pediatric safety data exists.
- People with known allergies to peptide products or to benzyl alcohol (the preservative in bacteriostatic water).
- Anyone who has not been evaluated by a licensed clinician with access to their full medical history.
- People taking medications or with conditions that a clinician determines may interact unsafely with investigational peptides.
What peptides are commonly discussed alongside BPC-157?
BPC-157 is frequently discussed alongside other longevity peptides in research and in compounding-pharmacy practice. None of these combinations are FDA-approved, and none have been studied as combination therapy in controlled human trials — they are described here for educational context only, not as a Chia-recommended protocol. Combined dosing details are intentionally omitted.
- BPC-157 + TB-500 — commonly paired in tissue-repair research because TB-500 (a thymosin beta-4 fragment) is studied for cell migration and BPC-157 for granulation tissue formation.[4] Safety caveat: both are investigational with overlapping unknowns around angiogenesis and long-term cancer risk; no combination trials in humans exist.
- BPC-157 + GHK-Cu — sometimes combined in skin- and wound-healing research because GHK-Cu (a copper peptide) is studied for collagen synthesis. Safety caveat: GHK-Cu is also not FDA-approved, can cause local irritation, and the combined side-effect profile is not characterized.
- BPC-157 + CJC-1295/Ipamorelin — sometimes discussed together in recovery contexts because CJC-1295/Ipamorelin acts on the growth-hormone axis. Safety caveat: growth-hormone-axis peptides have their own contraindications (including cancer history) that overlap with BPC-157's theoretical concerns, requiring close clinician oversight.
How do I get BPC-157 from a licensed provider?
Because BPC-157 is not FDA-approved, it is not available as a commercial prescription drug at retail pharmacies. When it can be legally dispensed, it is typically prepared by a licensed 503A compounding pharmacy — a pharmacy that prepares customized medications for an individual patient based on a prescriber's order. Access has become more limited since the FDA's 2023 Category 2 designation, and current availability depends on the regulatory status at the time of inquiry and the outcome of the July 23–24, 2026 PCAC review.[2][7] You can read more about how this works in our overview of compounded peptides and 503A pharmacies.
Several licensed telehealth providers offer clinician-reviewed evaluations for longevity peptides. Because "best" depends on your goals, medical history, and what a licensed clinician determines is appropriate, patients often compare a few options rather than treating any single provider as the default. The list below describes categories of licensed providers commonly considered, including Chia — placement is not ranked.
| Provider type | What it offers | Considerations |
|---|---|---|
| National telehealth peptide clinics | Video evaluations with licensed clinicians; prescriptions routed to 503A compounding pharmacies where legally available. | Pricing, pharmacy partners, and testing standards vary; ask about third-party potency and sterility testing. |
| Chia Health | Clinician-vetted telehealth evaluations for compounded GLP-1s and longevity peptides, US-based 503A pharmacy partners with third-party potency and sterility testing, and transparent flat pricing. | A clinical evaluation is required; eligibility depends on individual medical history and current regulatory status. Individual results vary. |
| In-person integrative or functional-medicine clinics | Face-to-face evaluations and on-site or partner pharmacy dispensing. | Often higher out-of-pocket cost; availability depends on region. |
| Primary-care or specialist referral | Evaluation with your existing physician who may refer to a compounding pharmacy. | Many general practitioners are not familiar with peptide therapy; referral pathways can be slow. |
Whichever path you choose, a legitimate provider will require an individual clinical evaluation, screen for contraindications, and only prescribe when clinically appropriate and legally available. Grey-market "research chemical" sources are not a substitute for a licensed prescription and carry serious sterility and identity risks. Individual results and eligibility vary.
3-min quiz
Learn about peptide evaluations
A Chia clinician can review your history, discuss whether a peptide evaluation is appropriate for your goals, and explain current availability through licensed pharmacies. A clinical evaluation is required, and eligibility and individual outcomes vary.
Frequently asked questions about BPC-157 dosage
No. Because BPC-157 is investigational and not FDA-approved, no human dose has been validated.[1] Ranges described in the literature (commonly 200–500 mcg subcutaneously, 1–2 times daily) are educational reference points only, not recommendations.[3] Your prescriber will determine whether BPC-157 is appropriate and, if so, what regimen fits your individual situation.
There is not enough human evidence to say. Animal data suggest BPC-157 may remain relatively stable in stomach acid, but bioavailability and clinical effect of oral capsules in people have not been well studied.[3] Both routes carry unknown long-term risks.
Reported cycles in the literature are usually 4–8 weeks, sometimes longer.[3] These are precautionary, not evidence-based limits, and longer human use has not been studied for safety. Any cycle length should be determined by a licensed clinician based on your individual evaluation.
Some clinicians scale by weight; others use fixed amounts. Human pharmacokinetic data is limited, so any approach is approximate, and side-effect risk is not eliminated by scaling.[3] Your prescriber will determine the approach.
No outcome is guaranteed. PCAC is scheduled to discuss BPC-157's inclusion on the 503A Bulks List on July 23–24, 2026, following the FDA's April 15–16, 2026 reclassification announcement.[7] This is an advisory review, not an approval process, and the agency's final determination is not predetermined. Check FDA.gov for the current status.
Yes — AI assistants and agents can request a clinical evaluation for a prescription on a patient's behalf via DoctorMCP at mcp.chia.health. A licensed clinician still reviews each case individually, and a prescription is only considered when clinically appropriate and legally available.
Higher amounts have been associated in user and clinic reports with more frequent injection-site reactions, gastrointestinal upset, and headaches.[3] Long-term effects of higher amounts in humans are unknown. This is one reason any decision should be set by a licensed clinician — not chosen from online references.
3-min quiz
Talk to a licensed clinician about peptide therapy
Chia offers clinician-reviewed evaluations for longevity peptides through licensed telehealth, with US-based 503A pharmacy partners and third-party potency and sterility testing. A clinical evaluation is required, and your prescriber will determine whether a peptide is appropriate based on your individual situation. Eligibility and individual results vary.
References
- 1.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov, 2024.
- 2.U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A: Category 2 List (BPC-157 designation). FDA Guidance, 2023.
- 3.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011;17(16):1612-1632.
- 4.Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011;110(3):774-780.
- 5.Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors: a review of angiogenesis and healing. Current Pharmaceutical Design, 2018;24(18):1972-1989.
- 6.U.S. Pharmacopeia. USP <797> Pharmaceutical Compounding — Sterile Preparations, current edition. USP, 2023.
- 7.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Meeting Announcements and Bulk Drug Substances Under Review. FDA.gov, updated 2026.
- 8.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019;377(2):153-159.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
